Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 17, 2007 Brian Lawler	QLT Stays the Course Sales of QLT's Visudyne, a drug to treat macular degeneration, continue to plummet due to competition. QLT plans to try to resuscitate.
The Motley Fool October 26, 2006 Brian Lawler	QLT Quickly Losing Traction The biotech company gets hammered by a competitor's superior product. There was one bright spot in the quarter for QLT, though. Investors, take note.
The Motley Fool April 24, 2007 Brian Lawler	Is the Worst Over for QLT? The biopharma announces another dismal quarter of declining sales for its top compound.
The Motley Fool March 31, 2008 Brian Lawler	A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration.
The Motley Fool July 5, 2006 Brian Lawler	Stay Away From QLT Competitive pressure on its top drug makes this company one investors should avoid.
The Motley Fool October 29, 2007 Brian Lawler	QLT in a Rut or Ready for a Comeback? QLT updates investors on its top drugs.
The Motley Fool January 21, 2005 Charly Travers	Seeing the Value in QLT A narrow-minded market could be creating a great drug value.
The Motley Fool November 29, 2007 Brian Lawler	QLT Goes on the Block QLT announced yesterday that it's in the preliminary stages of exploring a sale.
The Motley Fool April 25, 2005 Charly Travers	Where Is QLT going? The drug maker's upcoming conference call needs to address the question. Shares are down 30% since the beginning of the year. Can QLT turn this around?
The Motley Fool August 31, 2004 Charly Travers	Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one.
The Motley Fool June 8, 2007 Brian Lawler	QLT Eats Itself The beleaguered specialty pharmaceutical opens up another share buyback plan.
The Motley Fool May 24, 2005 Charly Travers	Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note.
The Motley Fool February 26, 2007 Brian Lawler	Is QLT the Comeback Kid? The Canadian drugmaker updates investors on its outlook for 2007.
The Motley Fool March 29, 2005 Charly Travers	A Biotech Value Play Sometimes you have to invest against the grain. Take a look at Canadian drug company QLT.
The Motley Fool August 22, 2005 Rich Duprey	Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies.
The Motley Fool February 23, 2005 Charly Travers	QLT Is Still a Value The market's concerns mean this Canadian drug company is being offered up at a great price.
The Motley Fool October 2, 2007 Brian Orelli	Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data.
The Motley Fool April 28, 2005 Charly Travers	QLT's a Clutch Performer Pharma continues to deliver growth through difficult times.
The Motley Fool September 12, 2006 Brian Lawler	Those Buybacks at QLT Is the biopharmaceutical repurchasing shares to make itself more attractive for an acquisition? Investors, take note.
The Motley Fool August 21, 2008 Brian Lawler	Regeneron's Results Clearing Up The drugmaker presents new data on a compelling candidate for macular degeneration treatment.
The Motley Fool May 31, 2005 Karl Thiel	Is Eyetech Better Than It Looks? If you're a born contrarian with a little spare mad money lying around, this biotech could be worth buying at these levels.
Chemistry World January 13, 2011 Andrew Turley	UK tilts towards appraisal of Avastin as eye drug The UK is moving closer to opening up the National Health Service to cancer drug Avastin (bevacizumab) for the treatment of eye conditions, such as age-related macular degeneration.
The Motley Fool January 3, 2005 Rich Duprey	Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA.
The Motley Fool March 18, 2008 Brian Lawler	QLT's Blemished Aczone Clears Up A more lenient label from the FDA is good news for this drugmaker.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool August 31, 2007 Brian Lawler	QLT Gets Reformulated Drug developer QLT announced that an EU approval will open new markets for the cancer drug that could edge out the competition by lowering overall medical costs.
The Motley Fool June 10, 2008 Brian Lawler	Allergan's Unblemished Deal Acquiring a niche acne drug from QLT provides clarity for both companies.
The Motley Fool February 11, 2005 Stephen D. Simpson	For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant.
Chemistry World September 24, 2014 Phillip Broadwith	Review says cheaper drug is safe for eye disease Researchers have added weight to the argument that health services should use the cancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration, instead of the more expensive Lucentis (ranibizumab).
The Motley Fool June 15, 2004 Charly Travers	QLT Swallows Atrix Atrix Laboratories has been purchased by Canadian drug company QLT. For Atrix shareholders, the timing of this deal must be incredibly frustrating.
Chemistry World April 2, 2015 Emma Stoye	Novartis accused of 'derailing' trials for cheap eye disease drug The British Medical Journal has accused pharmaceutical giant Novartis of deliberately hindering research into the use of anticancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration.
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
BusinessWeek August 16, 2004 Arlene Weintraub	The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near.
The Motley Fool June 21, 2005 Brian Gorman	Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note.
The Motley Fool October 26, 2004 Charly Travers	Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point.
The Motley Fool February 29, 2008 Brian Lawler	Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease.
The Motley Fool October 11, 2005 Stephen D. Simpson	Genentech Generates Profits Whether you call it a biotech or a pharmaceutical, there's no disputing that Genentech is raking in some big bucks. Trying to value this stock is no treat, but growth-oriented investors should still have much to look forward to over the years.
The Motley Fool January 5, 2005 Rich Duprey	Sharks Don't Go Blind Shark liver oil shows promise in treatment of age-related macular degeneration. Genaera Corp. though leading this interesting investigation, is not profitable, racking up some significant losses over the years.
The Motley Fool January 18, 2005 Charly Travers	Biotech Class of 2004 Hot drugs are leading to amazing stock performances. CoTherix... Eyetech Pharmaceuticals... Pharmion... etc.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
Chemistry World June 3, 2014 Phillip Broadwith	Drug companies rapped for anticompetitive behavior The Italian health ministry is following up on rulings from the country's competition authorities and demanding billions of euros in damages resulting from anticompetitive behavior.